³¯Â¥ |
¼¼¼Ç Á¦¸ñ |
½Ã°£ |
¿¬»ç |
¿¬»ç ¼Ò¼Ó |
¹ßÇ¥ Á¦¸ñ |
4¿ù 29ÀÏ(Åä) |
Àӻ󿬱¸¿¡ È°¿ë °¡´ÉÇÑ ÃֽŠÀ¯Àüü ±â¼ú |
09:00-09:10
(10')
|
¹Ú¿õ¾ç |
»ï¼º¼¿ïº´¿ø |
Opening |
09:10-09:50
(40')
|
±èÁ¤ÈÆ |
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ |
Beyond Avante-garde in Medicine: In vivo Genome Editing for Vision |
10:00-10:40
(40')
|
±è½ÃÇö |
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ |
Clinical Cancer Genomics and Personalized Medicine |
10:40-11:30
(40')
|
±èÇöÁ¦ |
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ |
High resolution multiomics toolkits for translational research |
6¿ù 3ÀÏ
(Åä)
|
À¯ÀüüºÐ¼®À» ÅëÇÑ ½Å°æ°èÁúȯ ¿¬±¸ |
09:00-09:40
(40')
|
ÀÌÁ¤È£ |
KAIST |
Somatic mosaicism in neurological disorders |
09:40-10:20
(40')
|
ÀÓº´Âù |
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ |
Exome and genome sequencing results in a large pediatric neurological disorders cohort |
10:20-11:00
(40')
|
¹®Àå¼· |
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ |
Genomic medicine for adult neurological disorders |
6¿ù 24ÀÏ
(Åä)
|
À¯ÀüüºÐ¼®À» ÅëÇÑ ½ÉÀå Áúȯ ¿¬±¸ |
09:00-09:30
(30')
|
¿ÀÀç¿ø |
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ |
TBD |
09:30-10:10
(40')
|
±è»ó¿ì |
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ |
Whole-genome sequencing for identifiying pathogenic variants in cardiomyopathy |
10:10-10:50
(40')
|
À̽ÂÇö |
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ |
TBD |
10:50-11:30
(40')
|
À̽ÂÇ¥ |
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ |
Identifying high cardiovascular risk populations using polygenic risk scores |
9¿ù 23ÀÏ
(Åä)
|
À¯ÀüüºÐ¼®À» ÅëÇÑ ¾ÏÁúȯ ¿¬±¸ |
09:00-09:30
(30')
|
Á¤½ÂÇö |
°¡Å縯´ëÇб³
ÀÇ°ú´ëÇÐ
|
À¯Àüü ºÐ¼®À» È°¿ëÇÑ ¾ÏÁøÈ ¿¬±¸ |
09:30-10:00
(30')
|
ÃÖÀ±Áø |
¼¿ï¼º¸ðº´¿ø |
À¯Àüü ºÐ¼®À» È°¿ëÇÑ ºÎÀÎ¾Ï ¿¬±¸ |
10:10-10:30
(20')
|
À¯Å°æ |
¾Æ»êº´¿ø |
¾×ü»ý°ËÀ» È°¿ëÇÑ À¯¹æ¾Ï ¿¬±¸ |
10:30-11:00
(30')
|
±èÈ¿Áø |
ºÐ´ç¼¿ï´ëº´¿ø |
º´¸®°Ëü¸¦ È°¿ëÇÑ ¾Ï À¯Àüü ¿¬±¸ |
11:10-11:40
(30')
|
ÇÑ¹Ì·É |
ÀÎõ´ëÇб³ |
Exome Sequencing Analysis in Clinical Research |
10¿ù 28ÀÏ
(Åä)
|
À¯ÀüüºÐ¼®À» ÅëÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼°ú °ËÁõ ¿¬±¸ |
09:00-09:20
(20')
|
À±Àç¿ø |
º¸ÈÆÀÇÇבּ¸¼Ò |
Introduction and challenges of liquid biopsy-based biomarkers |
09:20-10:00
(40')
|
À̽ÂÅ |
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ |
Discovering markers of cancer treatment response through genomic analysis |
10:00-10:40
(40')
|
¼±ÃæÇö |
Áö³ð¿ÀÇǴϾð |
Association biomarker discovery of Clonal hematopoiesis of indeterminate potential (CHIP) with target disease |
10:40-11:20
(40')
|
ÇѵµÇö |
¼¿ï´ëÇк´¿ø |
Proteomics ±â¹ýÀ» ÀÌ¿ëÇÑ ´Ü¹éÁú ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼ ¹× °ËÁõ |
11¿ù 25ÀÏ
(Åä)
|
À¯ÀüüºÐ¼®À» ÅëÇÑ ÇǺÎÁúȯ ¿¬±¸ |
09:00-09:20
(20')
|
Á¤±âÈÆ |
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ |
Introduction and exploration of immune cell diversity |
09:20-10:00
(40')
|
¾çÇѽ½ |
KAIST |
À¯Àüü ºÐ¼®À» È°¿ëÇÑ ÇǺÎÁٱ⼼Æ÷ ±âÃÊ¿¬±¸ |
10:00-10:40
(40')
|
±èÅÂ±Õ |
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ |
Application of single-cell omics to identify targetable biomarkers in inflammatory skin diseases |
10:40-11:20
(40')
|
½ÅÇöÅ |
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ |
°ø°ø À¯Àüü µ¥ÀÌÅ͸¦ È°¿ëÇÑ ÇǺÎÁúȯ¿¬±¸ |